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DWIAbstract Background: Diffusion weighted image (DWI) and dynamic contrast enhanced MR
imaging (DCE-MRI) provide excellent parameters that are useful for differentiating cancer from
normal tissue in prostatic cancer patients.
Purpose: To deﬁne the diagnostic value of diffusion weighted image (DWI) and dynamic contrast
enhanced MR imaging (DCE-MRI) and determine whether the combination of the two techniques
provides higher diagnostic accuracy for prostate cancer than each technique alone.
Material and methods: 30 patients suggested to have prostate cancer based on high PSA value
underwent MRI examination including axial T2-WI, diffusion weighted image (DWI), apparent
diffusion coefﬁcient (ADC) and dynamic contrast enhanced MRI (DCE-MRI). The ﬁnal diagnosis
was conﬁrmed by histopathological study of the TRUS-guided biopsies.
Results: The sensitivity of DCE-MRI, ADC at 1.2 and ADC at 1.4 in detection of prostatic
carcinoma was 100%, 84.6% and 100% respectively (P= 0.000). The highest validity for cancer
prostate is DCE-MRI (Kappa = 0.93) followed by ADC at 1.4 (Kappa = 0.86) then ADC at
1.2 (Kappa = 0.79).
Conclusions: DCE-MRI and DWI have high sensitivity to differentiate cancerous from non-
cancerous prostatic tissue, and the combination of both techniques increase the diagnostic accuracy
of prostatic cancer than each one alone.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by
Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer is one of the most common malignancies
in elderly men and preoperative identiﬁcation of localized
prostate cancer for early detection and staging are issues of
major concern and lead to a complete cure (1). The major goal
for prostate cancer imaging in the next decade is more accurate
disease characterization through the synthesis of anatomic,
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the potential to improve the identiﬁcation of prostate cancer
at an early stage (3).
Addition of dynamic contrast enhancement, spectroscopy,
and diffusion weighted imaging to standard T2-weighted
sequence is practical, and improves MRI of the prostate (4).
The principles of DCE-MRI are based on tumor angiogen-
esis, tumors produce factors that promote vessel formation
and increase permeability, compared with normal vessels (5).
The pattern of enhancement of the malignant prostatic tissue
is different from that of normal tissue (6).
Relative peak enhancement is the most accurate perfusion
parameter for prostatic cancer detection in both peripheral
and central zones (7). Previous studies demonstrated paramet-
ric imaging of the wash-in rate was more accurate for the
detection of prostate cancer in the peripheral zone; however,
there is a signiﬁcant overlap between the wash-in rate for
cancer and that for normal tissue in the transitional zone (8).
Time-signal intensity curves (TIC) from dynamic contrast-
enhanced MR imaging were classiﬁed into three types based
on their shapes (Fig. 1). The X-axis represents the number of
series in MR imaging expressed as (time in seconds) and the
Y-axis represents the signal intensity in arbitrary units (relative
enhancement) (9). The type A TIC was characterized by an
early peak enhancement and a time-to-peak value of no more
than 60 s .The type B TIC was characterized by an intermedi-
ate early enhancement and a time-to-peak value of no less than
60 s and not greater than 100 s. The type C TIC was character-
ized by delayed enhancement and no signal peak after a
continuous increase in signal intensity for 3 min (9).
DWI is based on the principle of random molecular motion
of water in tissues (10). Normal prostate tissue exhibits signal
loss, whereas areas of densely packed tumor cells reveal brightFig. 1 Time-signal intensity curves (TIC) from dynamic
contrast-enhanced MR imaging were classiﬁed into three types
based on their shapes. The onset time (a), the time to peak (b),
the wash-in rate (c), represent the velocity of enhancement and
deﬁned by d-c/b-a, where (d), represent the maximum (peak)
enhancement (9).on the raw DWI. The use of DWI enables the calculation of
the apparent diffusion coefﬁcient (ADC) (11).
1.1. Aim of work
The purpose of this study is to compare the diagnostic utility
of DWI (ADC map), DCE-MRI, and a combination of both
techniques in the localization and detection of prostatic cancer.
This study also assesses the feasibility of using DWI and/or
DCEI targeted-biopsy instead of random biopsy.2. Material and methods
A prospective study of thirty men (age range 36–83 years with
mean age = 69.7 years) suggested to have prostate cancer on
the basis of high PSA value (greater than 4.0 ng ml 701) or
abnormal per-rectal examination ﬁndings, DWI-MR and
dynamic contrast enhancement MRI using a 1.5 T supercon-
ducting MR system (Signa Excite HD; GE Healthcare,
Milwaukee, USA) with a 8-channel phased array coil, followed
by transrectal ultrasound (TRUS) biopsy using endorectal
biplane convex 7.5 MHz probe of ultrasound machine
(LOGIQ-9 GE Healthcare) to avoid post-biopsy hemorrhage
and inﬂammatory signals that may obstacle accurate interpre-
tation of gland images.
The study started in March 2012 and ﬁnished in November
2014. Informed consent was obtained from all cases, and
approval for this study was obtained from the ethics review
board of our institution.
Exclusion criteria included patients who have contraindica-
tion to MRI scanning and patients underwent prior hormonal
therapy or if prostatectomy was done following radiotherapy.
Histopathological diagnosis of prostate cancer had been
proven by TRUS biopsy in all cases.
2.1. Biopsy protocol
Before, the biopsy, the advantage and disadvantage of the
biopsy (including pre-procedure, procedure and post-
procedure recommendations) were explained to each patient
and written informed consent was obtained. We did biopsy
for questionable areas detected by MRI under TRUS-
guidance using automated spring-loaded 18-gauge biopsy
gun (Vitesse biopsy gun. Opti Med.). Using endorectal biplane
(convex 7.5 MHz) probe of ultrasound machine, more than
two biopsies for the suspected area by MRI were taken. All
biopsy specimens were labeled to determine the biopsy loca-
tion and all specimens were examined by one experienced
uropathologist.
2.2. MRI protocol
Conventional MRI consisted from, T2-weighted fast spin-echo
sequence were acquired in axial plain using the following
parameters {TR:6517, TE:121 /Ef, EC: 1/1 41.7 kHz,
FOV:24 · 24, 4.5 thk/0.5 sp, NEX:4.00 and matrix:
384 · 320}, axial T1-weighted fast spin-echo sequence using
the following parameters {TR:933, TE:11/Ef, EC:1/1
19.2 kHz, FOV:24 · 24, 5.5 thk/0.5 sp, NEX: 2.00 and
matrix:288 · 256} and sagittal T2-weighted fast spin-echo
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EC:1/1 50KHz, FOV:29 · 29, 4.0 thk/1.0sp, NEX:2.00 and
matrix:384 · 256). T2-weighted fast spin-echo sequence were
acquired in axial plain, axial T1-weighted fast spin-echo
sequence and sagittal T2-weighted fast spin-echo sequence.
Axial DWI was obtained by using a single-shot spin-echo-
planar imaging sequence (EPI) with the following parameters:
3400/117 and b value of 0 and 1000 s/mm2, along all three
directions in the axial plane. Full echo information was
obtained with a band width of 1220 Hz/pixel and a matrix size
of 256 · 156, the ﬁeld of view was 22 cm, with 4-mm section
thickness and no intersection gap, including the entire prostate
and seminal vesicle, the orientation and location of these
images were identical to the axial T2-weighted images. The
use of DWI facilitates the calculation of the apparent diffusion
coefﬁcient (ADC), the quantitation analysis of ADC is accom-
plished retrospectively on a scanner window. The ADC maps
were converted to 8-bit gray-scale images with window width
(WW) of 121, 971, 1030 and window level (WL) of 485, 515,
605, with this method, regions of low ADC were darker than
regions of high ADC, with areas less than or equal to
1 · 103 mm2/s. being black.
2.3. Dynamic contrast-enhancement MR imaging
Currently no standard MR imaging protocol for dynamic con-
trast enhancement MR examination has been completely
established for prostate imaging (12), but in our institution,
we use a modiﬁed LAVA technique (liver acquisition with vol-
ume acquisition) by performing a 3D-axial T1-weighted fast
spoiled gradient-recalled echo LAVA sequences with the fol-
lowing parameters: TR:4.2,TE:2, EC:1/1 62.5 kHz, TI:7,
OV:24 · 24, matrix: 256 · 256, 4.0 thk/-2.0 ov, zeroﬁll interpo-
lation process with PI during triphasic acquisition of entire
prostate after contrast infusion at arterial, venous and delayed
phase of contrast administration, in which 5 identical
sequences of 40 slices every 10 s for 14 s. each (acquisition
duration), started immediately after administration of contrast
agent, gadoteric acid (Dotarem, Guerbet, Roissy Cdg, France)
at dose of 0.1 mmol/kg and rate of 3 ml/s via an automatic-
injector, followed by 20 ml. ﬂush of saline. Dynamic MR
Images were transferred to a diagnostic workstation, and
dynamic MR analysis software was used for the evaluation.
The DCE-MRI and DWI were analyzed by commercial
software (Functool; GE Healthcare, Milwaukee, USA), for
image post-processing, parametric map generation and ROI
enhancement measurement, correlation between the initial sus-
picious DCE-MRI ﬁndings and the DWI region of interest
(ROI) was performed.
In these maps, the strongly enhanced lesions appear red,
intermediate enhanced lesions appear orange or yellow,
whereas low enhanced lesions appear green.
Focal regions with large positive enhancement integral val-
ues are indicative of tumor involvement. For both the right
and left peripheral zones, one slice was selected if there is
strongly enhanced lesion in comparison with the surrounding
tissue was detected and the region of interest (ROI) was placed
and traced on the enhanced lesion on a consensus basis by us.
If strongly enhanced lesion was not visible, a slice through the
middle of the gland was selected and a ROI was placed over
the area encompassing both peripheral zones. For the rightand left inner glands, a slice through the middle of the gland
was selected and ROIs were placed over the area encompassing
both sides of the inner gland because there was inhomoge-
neous enhancement from coexisting benign prostatic hyper-
plasia in many cases (9).
2.4. Quantiﬁcation of enhancement
A time-intensity curve (TIC) for each site was obtained from
the dynamic images. TICs were classiﬁed into three types based
on their shapes (1).
For the peripheral zone sites, we deﬁned type A and B TICs
as positive and type C TIC as negative on DCE-MRI. Most
normal peripheral zones did not show hypervascularity. As
to the inner gland sites, normal inner glands and coexisting
BPH often showed moderate vascularity, thus, we deﬁned only
type A TIC as positive and type B and C TICs as negative on
DCE-MRI.
3. Results
In 30 patients, serum PSA exceeded normal range (PSA was
greater than 4.0 ng/ml). Digital rectal examination (DRE)
was positive for suspecting malignancy in 4 patients (by pal-
pating hard prostatic mass) and negative for 9 patients (no def-
inite palpable prostatic masses). Patient were comprehensively
evaluated for cancer detection, localization and staging with
PSA, DRE, Noncontrast enhanced MRI (T2-WI,DWI &
ADC maps), DCE-MRI and TRUS MRI-Targeted biopsy,
cancer was detected in 13 patients (Figs. 2–4) with Gleason
scores ranged from 3 to 10. Prostate cancer was excluded in
17 patients (Fig. 5). DWI was not sensitive in detection of pro-
static cancer. The 13 patients diagnosed as cancer prostate
underwent surgical intervention.
Central zone (CZ) biopsied in 15 patients, transitional zone
(TZ) in 5 patients and peripheral zone (PZ) in 10 patients,
biopsies were taken from 2 sites in 11 patients and 3 sites in
19 patients (Table 2). The ﬁnal diagnosis was adenocarcinoma
in 13 cases, benign prostatic hyperplasia in 14 cases, prostatic
hyperplasia with prostatitis in 2 cases and nodular prostatic
hyperplasia in one case (Table 2).
The sensitivity of DCE-MRI, ADC at 1.2 and ADC at 1.4 in
detection of prostatic carcinoma was 100%, 84.6% and 100%
respectively (Table 1), while the sensitivity of the PSA was
76.9%. So the highest validity for cancer prostate is DCE-
MRI (Kappa = 0.93) followed by ADC (Fig. 6) at 1.4
(Kappa = 0.86) then ADC at 1.2 (Kappa = 0.79). ADC
showed the highest agreement with DCE-MRI (Tables 2 and 3).
The accuracy of DCE-MRI in detection of cancer prostate
was 96.7%, the accuracy of ADC at 1.2 · 103 mm2/s and at
1.4 · 103 mm2/s was 90% and 93.3% respectively. The over-
all accuracy when adding ADC at 1.4 with DCE-MRI was
96.7%, while the accuracy of PSA was 66.7%.
4. Discussion
T2WI provides high-resolution images that clearly deﬁne
prostate anatomy. DWI measures the diffusion of water
molecules through tissue in the presence of a strong magnetic
ﬁeld and radiofrequency pulses. Prostate cancer exhibits a
Fig. 2 Biopsy-proved adenocarcinoma in a 75-year-old man (a) Axial T2-weighted image shows an area of low signal intensity (arrow)
in the left peripheral zone. (b) Axial diffusion-weighted image shows high signal intensity in the same area (arrow). (c) ADC maps show a
low signal and ADC value in the same area (arrow). (d) Wash-in MR image shows a higher wash-in rate in the same area (arrow) than in
other areas. (e) Wash-out MR image shows a higher washout rate in the same area (arrow) than in other areas. (f) Time-signal intensity
curve from dynamic contrast-enhanced MR imaging shows faster and stronger enhancement and post-initial plateau curve.
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Fig. 3 Biopsy-proved adenocarcinoma in 70-year-old man (a) Axial T2-weighted image shows an area of low signal intensity (arrow) in
the center of peripheral zone. (b) Axial diffusion-weighted image shows high signal intensity in the same area (arrow). (c) ADC maps show
a low signal and ADC value in the same area (arrow). (d) Wash-in MR image shows a higher wash-in rate in the same area (arrow) than in
other areas. (e) Wash-out MR image shows a higher washout rate in the same area (arrow) than in other areas. (f) Time-signal intensity
curve from dynamic contrast-enhanced MR imaging shows faster and stronger enhancement and post-initial rapid washout curve.
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Fig. 4 Biopsy-proved adenocarcinoma in a 82-year-old man (a) Axial T2-weighted image shows an area of low signal intensity (arrows)
in the left central and both peripheral zones, it inﬁltrates the posterior capsule with bulge beyond prostatic margin and lateral recto-
prostatic angle effacement (arrow heads) caused by peripheral zone tumor. (b) Axial diffusion-weighted image shows high signal intensity
in the same area (arrow). (c) ADC maps shows a low signal and ADC value in the same areas (arrow), moreover, diffusion shows area of
restriction diffusion in the left pubic ramus. (d) Wash-in MR image shows a higher wash-in rate in the same areas (arrow) than in other
areas. (e) Wash-out MR image shows a higher washout rate in the same area(arrow) than in other areas. (f) Time-signal intensity curve
from dynamic contrast-enhanced MR imaging shows faster and stronger enhancement and post-initial rapid wash-out curve, the
abnormal area at diffusion shows rapid strong wash-in with post-initial plateau curve of metastatic deposit.
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Fig. 5 Biopsy-proved nodular prostatic hyperplasia in 83-year-old man (a) Axial T2-weighted image shows suspicious area of low signal
intensity (arrow) in the left PZ. (b) Axial diffusion-weighted image shows high signal intensity in the same area (arrow). (c) ADC maps
show a low signal and high ADC value in the same area (arrow). (d) Wash-in MR image shows a higher wash-in rate in the same area
(arrow) than in other areas. (e) Wash-out MR image shows similar washout rate in the same area (arrow) as other areas. (f) Time-signal
intensity curve from dynamic contrast-enhanced MR imaging shows faster and stronger enhancement and post-initial persistent rising
curve.
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DCE-MRI 13 16 100.0 94.1 92.9 100.0 0.93 0.000
ADC at
1.2 · 103mm2/s
11 16 84.6 94.1 91.7 88.9 0.79 0.000
ADC at
1.4 · 103mm2/s
13 15 100.0 88.2 86.7 100 0.86 0.000
PSA at 17.6 10 10 76.9 58.5 58.8 76.9 0.34 0.05
DWI: diffusion weighted image (·103 mm2/s) & ADC: Apparent Diffusion Coefﬁcient & PPV: positive predictive value & NPV: Negative
predictive value & DCE: Dynamic contrast enhancement & PSA: prostatic surface antigen.












2 sites 11 36.7
3 sites 19 63.3
Site of biopsy
CZ (central zone) 15 50
TZ (transional zone) 5 16.7
PZ (peripheral zone) 10 33.3
Final diagnosis
Adenocarcinoma 13 43.3
Benign prostatic hyperplasia 14 46.7
Prostatic hyperplasia with prostatitis 2 6.7
Nodular prostatic hyperplasia 1 3.3
Fig. 6 ROC curve showing validity of ADC value in diagnosis of
cancer prostate.





A (N= 14) B & C (N= 16)
ADC 1.2 · 103 mm2/s
Abnormal 11 1 0.73 0.000
Normal 3 15
ADC 1.4 · 103mm2/s
Abnormal 14 1 0.93 0.000
Normal 0 15
PSA
Abnormal 10 7 0.27 0.12
Normal 4 9
ADC showed the highest agreement with DCE-MRI one case
overestimated as malignant by DCE-MRI. (DCE: Dynamic con-
trast enhancement & DWI: diffusion weighted image & ADC:
apparent diffusion coefﬁcient & PSA: prostatic surface antigen).
1200 S. Zidan, H.I. Tantawyreduced diffusion of water compared to normal prostate tis-
sue due to its tightly packed cells with a relative decrease
in water content (13).
The glandular-ductal tissues have lower peak enhancement
(PE) and higher (ADC) than the stromal-low ductal tissues (14).
In our study, benign prostatic lesions were more common
than malignant lesions, benign lesions were diagnosed in 17
cases; 10 cases of them were in the central zone, 4 cases were
in the peripheral zone and 3 cases were in the transitional zone,
while malignant lesions (cancer prostate) were diagnosed in 13
cases which were more common in the peripheral zone (6
cases) followed by central zone (5 cases) then the transitional
zone (2 cases) and these results agreed with that of Manenti
et al. (15).
Our study showed that prostatic cancer detected by T1-WI,
DCE-MRI and ADC maps is more accurate than that detected
by DWI and T2-WI all over the whole different prostatic zones
with sensitivity and speciﬁcity reach 100% and 94%
respectively at DCE-MRI and at lower ADC value
(1.4 · 10–3 cm/mm2) the sensitivity and speciﬁcity reach
Prostate carcinoma: Accuracy of diagnosis 1201100% and 88% respectively, by this way our results may add a
new idea than before which mentioned that DWI should be
combined with T2WI. It have shown that DWI combined with
T2WI has superior diagnostic accuracy to T2WI alone, with
sensitivity and speciﬁcity of 85–90% and ROC-AUC of
0.80–0.90 when compared to radical prostatectomy ﬁndings
(7,16,17).
At the same time our results are complementary to results
obtained by AbdelMaboud et al. (18), who stated that pro-
static cancers had lower ADC value than that of the healthy
prostate, it was 1.484 ± 0.289 · 10–3 mm2/s for the
histopathologically proven benign peripheral zone, and
0.737 ± 0.154 · 10–3 mm2/s for the histopathologically proven
cancer prostate.
In our study the demonstration of prostate cancer arising
from inner gland is difﬁcult than in peripheral gland in which,
in the peripheral zone the sensitivity of DCE and ADC maps
was similar but the speciﬁcity and accuracy of DCE were
greater than DCE-MRI, however ADC maps were good in
excluding cancer in which four positive sites on DCE-MRI
(giving rise to type B TIC) were negative on ADC maps among
the histolopathologically conﬁrmed benign sites and our ﬁnd-
ings are compatible with those of Emad-Eldin et al. (19) who
stated that the CZ and PZ of normal prostate were easily dis-
criminated on diffusion and ADC images. (The signal intensity
of BPH nodule was non-homogeneous and lower than that of
PZ on ADC map.) Prostatic cancer showed high signal inten-
sity on DWI and low signal intensity on ADC map.
The mean ADC value of prostate carcinoma was signiﬁ-
cantly lower than that of normal CZ, PZ, and BPH nodule
(P< 0.05). The PZ tissue had a signiﬁcantly higher ADC
value than CZ (P< 0.05). The ADC value of BPH lesions
was signiﬁcantly lower than that of CZ (P< 0.05).
Thus, hypervascularity denoted by type B TICs at periph-
eral zone may not be judged as positive for cancer in contrast
to type A TICs; however these results approximate the results
obtained by Kozlowski et al. (20) that stated that the sensitiv-
ity and speciﬁcity values were 54% and 100% respectively for
the ADC data, and 59% and 74% respectively for DCE-MRI
data. But evaluation of this result with larger number of
patients with prostate cancer or hypervascular lesions will be
necessary.
According to our study, type A dynamic enhanced curve in
kinetic evaluation of prostatic lesion was detected in all PC at
different zones and one benign case at peripheral zone and
type C curve was detected in all benign cases at central and
transitional zone and type B curve at all benign cases of
peripheral zone as mentioned before in addition to some cases
at central zones which is compatible with other results stated
that DCE-MRI is less operator dependent, and high-
temporal resolution DCE-MRI can be used to detect the
ﬁrst-pass of a contrast agent providing quantitative modeling
parameters. Turnbull et al. (21) successfully differentiated
prostate cancer from BPH using a two-compartment simplex
minimization technique, in which the concentration of Gd-
DTPA is assumed to be proportional to the relative increase
in FSPGR signal.
Engelbrecht et al. (7) evaluated methods that were shown to
provide more accurate estimations of pharmacokinetic param-
eters. Quantitative DCE-MRI might therefore have the capac-
ity to visualize the focus of cancer within the inner gland of the
prostateIn central and transitional zones the sensitivity, speciﬁcity
and accuracy of DCE-MRI were greater than ADC maps, par-
ticularly when type A TIC was deﬁned as positive, in which
three positive sites on DCE-MRI were negative on ADC maps
among histopathologically conﬁrmed cancer sites and this
result is in agreement with those by Ito et al. (9) who stated
the visualization of prostate cancers arising from the inner
gland is difﬁcult because coexisting BPH may produce a signal
similar to that of cancer nodules with marked vascularity and
when type A and B TICs were deﬁned as positive sensitivity
improved but speciﬁcity was substantially reduced.
Therefore, we suggest that the ADC map is helpful as a
supplement to DCE-MRI images rather than as a substitute
for DCE-MRI images and this is agreed with the results
obtained by Lim et al. (22).
Based on our current results, unenhanced MRI (comprised
of DWI, ADC maps and T2-WI) cannot be replaced by DCE-
MRI for accurate detection of prostatic, although the accuracy
and sensitivity of both imaging techniques were not signiﬁ-
cantly different and however our results are disagreeing with
that obtained by Iwazawa et al. (23) who stated that detection
of central-gland cancer by DCE-MRI alone and by DWI alone
was nearly equal. On the other hand the detection of central
gland cancer by T2-WI or DCE-MRI is often difﬁcult because
of zonal T2 contrast between cancer and normal tissue is rela-
tively low, in addition, central gland tissue is more susceptible
to enhancement with gadolinium resulting in insufﬁcient con-
trast between cancer tissue and normal tissue, our explanation
for this difference is that we use dynamic, kinetic evaluation of
benign and malignant tissues which agreed with recent
authors, such as Delongchamps et al. (24) who stated that with
the usage of DCE-MRI is able to assess tissue vascularization
via the acquisition of contrast-enhanced T1-weighted
sequences measuring speciﬁc parameters, such as time to peak
enhancement and time to wash-out.
In this respect, DCE-MRI is superior to other imaging
modalities but could not replace them due to the need of speci-
ﬁc beneﬁt of each of them. In addition we found that T1-WI
DCE-MRI was the only sequence that can detect extra-
glandular extension and as a result played critical role in stag-
ing of disease as well as plane strategy of treatment which
agreed with the results from different studies including
Villers et al. (3) showed that DCE-MRI is one of the tools that
help in pre-operative identiﬁcation of these anterior cancers. It
was also conﬁrmed by Akin et al. (25).
In our study, we depend on all MR sequence acquisition
analysis to guide prostatic biopsy and this agreed with
Vargas and Hricak (26) who mentioned that multiple MRI
sequences were used to guide prostate biopsies is important
to clarify the interpretability of the results decrease the proba-
bility of inconsistent or incompatible results due to differences
in targeting approaches.
Our results showed that MRI-targeted biopsy is an accurate
technique for detecting and quantifying intra-capsular tumor
as well as benign lesions with a sensitivity approached 100%,
which agreed with the result obtained by Tanimoto et al.
(27), in which forty-four prostate cancers were detected by
biopsy in a series of 83 patients who had pre-biopsy DWI,
DCE-MRI in combination with T2-WI. The sensitivity for
the detection of the prostate cancer was 95% and also, we
agreed with the meta-analysis obtained by Moore et al. (28)
who found that while MRI-targeted and standard biopsy
1202 S. Zidan, H.I. Tantawyapproaches detected cancer at similar rates, the MRI-targeted
approach decreased the diagnosis of clinically insigniﬁcant
cancers and reduced the percentage of men with abnormal
prostate-speciﬁc antigen or digital rectal examination ﬁndings
that required biopsy.
In our study we used 8-channel pelvic phased-array coil
(PPA) as it is better than endorectal coil in providing
excellent image quality in prostate MRI because of high
spatial resolution, which agreed with other author like
Husband et al. (29).
One interesting thing in this study is that we use modiﬁed
LAVA (liver acquisition with volume acquisition) technique
consists of 3-D T1-weighted gradient echo-sequence with opti-
mized fat sat fulﬁlls at last the need to acquire dynamic image
during arterial and venous phases after injection with high in-
plane and through-plane spatial resolution which agreed with
other authors like Verma and Rajesh (12), who mentioned
that, there is currently no standard protocol for DCE-MRI
of the prostate, but DCE-MRI of the prostate is usually per-
formed using a fast imaging sequence. Three-dimensional
gradient-echo sequences enable the entire prostate to be
imaged in a few seconds.Conﬂict of interest
The authors declare that there are no conﬂict of interest.References
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